Protagonist Therapeutics PTGX Stock
Protagonist Therapeutics Price Chart
Protagonist Therapeutics PTGX Financial and Trading Overview
| Protagonist Therapeutics stock price | 26.65 USD |
| Previous Close | 28.72 USD |
| Open | 28.49 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 900 |
| Day's Range | 28.12 - 28.93 USD |
| 52 Week Range | 7.24 - 30.1 USD |
| Volume | 718.29K USD |
| Avg. Volume | 1.05M USD |
| Market Cap | 1.64B USD |
| Beta (5Y Monthly) | 1.962676 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.39 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.4 USD |
PTGX Valuation Measures
| Enterprise Value | 1.42B USD |
| Trailing P/E | N/A |
| Forward P/E | -12.05042 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1911.487 |
| Price/Book (mrq) | 6.825321 |
| Enterprise Value/Revenue | 1649.078 |
| Enterprise Value/EBITDA | -9.753 |
Trading Information
Protagonist Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.962676 |
| 52-Week Change | 264.88% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 30.1 USD |
| 52 Week Low | 7.24 USD |
| 50-Day Moving Average | 24.59 USD |
| 200-Day Moving Average | 15.22 USD |
PTGX Share Statistics
| Avg. Volume (3 month) | 1.05M USD |
| Avg. Daily Volume (10-Days) | 792.45K USD |
| Shares Outstanding | 57.25M |
| Float | 45.05M |
| Short Ratio | 3.22 |
| % Held by Insiders | 1.67% |
| % Held by Institutions | 104.09% |
| Shares Short | 3.06M |
| Short % of Float | 5.41% |
| Short % of Shares Outstanding | 5.34% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -17029.45% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -31.089% |
| Return on Equity (ttm) | -54.13% |
Income Statement
| Revenue (ttm) | 859K USD |
| Revenue Per Share (ttm) | 0.02 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 26.58M USD |
| EBITDA | -145250000 USD |
| Net Income Avi to Common (ttm) | -140188000 USD |
| Diluted EPS (ttm) | -2.81 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 230.76M USD |
| Total Cash Per Share (mrq) | 4.03 USD |
| Total Debt (mrq) | 3.06M USD |
| Total Debt/Equity (mrq) | 1.42 USD |
| Current Ratio (mrq) | 10.148 |
| Book Value Per Share (mrq) | 4.202 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -104818000 USD |
| Levered Free Cash Flow (ttm) | -52034876 USD |
Profile of Protagonist Therapeutics
| Country | United States |
| State | CA |
| City | Newark |
| Address | 7707 Gateway Boulevard |
| ZIP | 94560-1160 |
| Phone | 510 474 0170 |
| Website | https://www.protagonist-inc.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 103 |
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Q&A For Protagonist Therapeutics Stock
What is a current PTGX stock price?
Protagonist Therapeutics PTGX stock price today per share is 26.65 USD.
How to purchase Protagonist Therapeutics stock?
You can buy PTGX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Protagonist Therapeutics?
The stock symbol or ticker of Protagonist Therapeutics is PTGX.
Which industry does the Protagonist Therapeutics company belong to?
The Protagonist Therapeutics industry is Biotechnology.
How many shares does Protagonist Therapeutics have in circulation?
The max supply of Protagonist Therapeutics shares is 59.14M.
What is Protagonist Therapeutics Price to Earnings Ratio (PE Ratio)?
Protagonist Therapeutics PE Ratio is now.
What was Protagonist Therapeutics earnings per share over the trailing 12 months (TTM)?
Protagonist Therapeutics EPS is -1.39 USD over the trailing 12 months.
Which sector does the Protagonist Therapeutics company belong to?
The Protagonist Therapeutics sector is Healthcare.
Protagonist Therapeutics PTGX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}